Literature DB >> 12586203

Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex.

Naoe Okamura1, Kenji Hashimoto, Nobuhisa Kanahara, Eiji Shimizu, Chikara Kumakiri, Naoya Komatsu, Masaomi Iyo.   

Abstract

An atypical antipsychotic drug, zotepine, which is pharmacologically and clinically related to clozapine, has unique therapeutic effects on patients with schizophrenia. It has been demonstrated that clozapine blocks neurotoxicity in the rat retrosplenial cortex induced by administration of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine ((+)-MK-801). We examined whether or not zotepine has the ability to block neurotoxicity in the rat retrosplenial cortex induced by administration of dizocilpine. Female Sprague-Dawley rats were injected intraperitoneally (i.p.) with vehicle (1 mg/kg), zotepine (5, 10 or 20 mg/kg) or clozapine (20 mg/kg). Fifteen minutes later, animals were injected intraperitoneally (i.p.) with vehicle (1 ml/kg) or dizocilpine (0.5 mg/kg). Neuropathological changes (neuronal vacuolization) were assessed 4 h after administration of dizocilpine. Immunohistochemical analysis of heat shock protein HSP-70, a marker of reversible neuronal injury, was performed 24 h after administration of dizocilpine. The pretreatment with zotepine (5, 10 or 20 mg/kg) significantly decreased the number of vacuolized neurons in the rat retrosplenial cortex 4 h after the administration of dizocilpine (0.5 mg/kg), in a dose-dependent manner. The potency of zotepine (20 mg/kg) for dizocilpine-induced neurotoxicity was similar to that of clozapine (20 mg/kg). Furthermore, similar to the case with clozapine (20 mg/kg, i.p.), zotepine (20 mg/kg, i.p.) significantly attenuated the expression of HSP-70 in the rat retrosplenial cortex induced by dizocilpine (0.5 mg/kg, i.p.). The present study suggests that the neuroprotective effects of zotepine- on dizocilpine-induced neurotoxicity are equipotent to those of clozapine. Based on the NMDA receptor hypofunction hypothesis of schizophrenia, the efficacy of zotepine in this study may partly contribute to the unique therapeutic effects of zotepine in patients with schizophrenia. Copyright 2003 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586203     DOI: 10.1016/s0014-2999(03)01303-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

Review 2.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

3.  Homocysteine levels in patients with schizophrenia on clozapine monotherapy.

Authors:  Adam Wysokiński; Iwona Kłoszewska
Journal:  Neurochem Res       Date:  2013-07-20       Impact factor: 3.996

4.  Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology.

Authors:  Irina G Stavrovskaya; Malini V Narayanan; Wenhua Zhang; Boris F Krasnikov; Jill Heemskerk; S Stanley Young; John P Blass; Abraham M Brown; M Flint Beal; Robert M Friedlander; Bruce S Kristal
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.